Episode Details
Back to Episodes
Bicara’s Ficera Breakthrough and Leadership Shift | Business and Finance News
Description
Bicara Therapeutics is on a fast track to revolutionize cancer treatment with its drug ficera, showing dramatic survival gains in head and neck cancer trials while maintaining safety—thanks to TGF-beta inhibition. The company’s leadership is shifting next year, with Ryan Cohlhepp taking the helm as CEO and founder Claire Mazumdar Clemon stepping into a strategic advisory role, setting the stage for commercialization. Jenn Larson joins as CFO to support scaling operations, as Bicara prepares for potential accelerated approval. With nearly $500M in cash, they’re advancing pivotal studies, launching a new dosing trial, and exploring applications in colorectal and anal canal cancers—all aimed at delivering life-changing care to patients who need it most.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/62675eea5c46e1e0